Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastases

Current Oncology

Volumn 20, Issue 4, 2013, Pages

  Ali, A ^a   Goffin, J R ^b   Arnold, A ^b   Ellis, P M ^b  

^a KING FAHAD MEDICAL CITY   (Saudi Arabia)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Chemotherapy; Early prognosis; Late prognosis; Whole brain radiation

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; BRAIN METASTASIS; BRAIN SURGERY; CANADA; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PATIENT SELECTION; RETROSPECTIVE STUDY; SURVIVAL TIME; TERTIARY HEALTH CARE;

EID: 84881236515     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.20.1481     Document Type: Article

References (30)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Canadian Cancer Society's Steering Committee. Canadian Cancer Statistics 2010. Toronto, ON: Canadian Cancer Society; 2010.
3. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase iii study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the tax 326 study group. J Clin Oncol 2003;21:3016-24.
4. Schiller JH, Harrington D, Belani CP, et al. on behalf of the Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8.
5. Robinet G, Barlesi F, Gervais R, et al. Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small cell lung cancer (nsclc) with measurable asymptomatic inoperable brain metastases (bm): a multicenter phase ii trial (gfpc 07-01) [abstract 7595]. J Clin Oncol 2010;28:. [Available online at: http://meetinglibrary.asco.org/content/47370-74; cited May 31, 2013]
6. Schuette W. Treatment of brain metastases from lung cancer: chemotherapy. Lung Cancer 2004;45(suppl 2):S253-7.
7. Louie AV, Rodrigues G, Yaremko B, et al. Management and prognosis in synchronous solitary resected brain metastasis from non-small cell lung cancer. Clin Lung Cancer 2009;10:174-9.
8. Al-Shamy G, Sawaya R. Management of brain metastases: the indispensable role of surgery. J Neurooncol 2009;92:275-82.
9. Bernardo G, Cuzzoni Q, Strada MR, et al. First-line chemotherapy with vinorelbine, gemcitabine, and carboplatin in the treatment of brain metastases from non-small-cell lung cancer: a phase ii study. Cancer Invest 2002;20:293-302.
10. Penel N, Brichet A, Prevost B, et al. Prognostic factors of synchronous brain metastases from lung cancer. Lung Cancer 2001;33:143-54.
11. Flannery TW, Suntharalingam M, Kwok Y, et al. Gamma knife stereotactic radiosurgery for synchronous versus metachronous solitary brain metastases from non-small cell lung cancer. Lung Cancer 2003;42:327-33.
12. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990;322:494-500.
13. Greig NH. Chemotherapy of brain metastases: current status. Cancer Treat Rev 1984;11:157-86.
14. Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase iii results of the rtog 9508 randomized trial. Lancet 2004;363:1665-72.
15. Vecht CJ, Haaxma-Reiche H, Noordijk EM, et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol 1993;33:583-90.
16. Sánchez de Cos J, Sojo González MA, Montero MV, Pérez Calvo MC, Vicente MJ, Valle MH. Non-small cell lung cancer and silent brain metastasis. Survival and prognostic factors. Lung Cancer 2009;63:140-5.
17. Bradbury PA, Twumasi-Ankrah P, Ding K, et al. The impact of brain metastases on overall survival (os) in National Cancer Institute of Canada Clinical Trials Group (ncic ctg) clinical trials (ct) in advanced non-small cell lung cancer (nsclc). J Clin Oncol 2009;27:. [Available online at: http://meetinglibrary.asco.org/content/32489-65; cited May 31, 2013]
18. Bindal AK, Bindal RK, Hess KR, et al. Surgery versus radiosurgery in the treatment of brain metastases. J Neurosurg 1996;84:748-54.
19. Wroński M, Arbit E, Burt M, Galicich JH. Survival after surgical treatment of brain metastases from lung cancer: a follow-up study of 231 patients treated between 1976 and 1991. J Neurosurg 1995;83:605-16.
20. Abrahams JM, Torchia M, Putt M, Kaiser LR, Judy KD. Risk factors affecting survival after brain metastases from non- small cell lung carcinoma: a follow-up study of 70 patients. J Neurosurg 2001;95:595-600.
21. Bindal RK, Sawaya R, Leavens ME, Lee JJ. Surgical treatment of multiple brain metastases. J Neurosurg 1993;79:210-16.
22. Nakagawa H, Miyawaki Y, Fujita T, et al. Surgical treatment of brain metastases of lung cancer: retrospective analysis of 89 cases. J Neurol Neurosurg Psychiatry 1994;57:950-6.
23. Robinet G, Thomas P, Breton JL, et al. Results of a phase iii study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small cell lung cancer: Groupe Francais de Pneumo-Cancerologie (gfpc) protocol 95-1. Ann Oncol 2001;12:59-67.
24. Olson JJ, Paleologos NA, Gaspar LE, et al. The role of emerging and investigational therapies for metastatic brain tumors: a systematic review and evidence-based clinical practice guideline of selected topics. J Neurooncol 2010;96:115-42.
25. Improta G, Zupa A, Fillmore H, et al. Protein pathway activation mapping of brain metastasis from lung and breast cancers reveals organ type specific drug target activation. J Proteome Res 2011;10:3089-97.
26. Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (rpa) of prognostic factors in three Radiation Therapy Oncology Group (rtog) brain metastases trials. Int J Radiat Oncol Biol Phys 1997;37:745-51.
27. Weltman E, Salvajoli JV, Brandt RA, et al. Radiosurgery for brain metastases: a score index for predicting prognosis. Int J Radiat Oncol Biol Phys 2000;46:1155-61.
28. Lorenzoni J, Devriendt D, Massager N, et al. Radiosurgery for treatment of brain metastases: estimation of patient eligibility using three stratification systems. Int J Radiat Oncol Biol Phys 2004;60:218-24.
29. Golden DW, Lamborn KR, McDermott MW, et al. Prognostic factors and grading systems for overall survival in patients treated with radiosurgery for brain metastases: variation by primary site. J Neurosurg 2008;109(suppl):77-86.
30. Langer CJ, Mehta MP. Current management of brain metastases, with a focus on systemic options. J Clin Oncol 2005;23:6207-19.